Latest research on G-CSF

Filgrastim is a recombinant, non-pegylated human granulocyte colony stimulating factor (G-CSF) analogue manufactured by recombinant DNA technology using a strain of E. coli. It is marketed as the brand name Neupogen by Amgen. Chemically, it consists of 175 amino acid residues. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine necessary for expression in E coli. Tbo-filgrastim, which is marketed by Sicor Biotech and FDA approved on August 29, 2012, contains the same active ingredient as Neupogen and is biologically similar, but it is formulated to be short-acting. On March 6, 2015, the FDA approved the biosimilar Zarxio (filgrastim-sndz) and is indicated for use in the same conditions as Neupogen. Zarxio is marketed by Sandoz.

G-CSF interactions

Oxygen uptake was measured with a metabolic cart (Vmax N29; Sensormedics, Yorba Linda, California, USA), calibrated before each test according to the manufacturer instructions, with high-grade calibration gasses (Carburos Metálicos, Las Palmas de Gran Canaria, Spain). [source, 2016]
This is reversible by the administration of Granulocyte Colony Stimulating Factor (G-CSF) which leads to blood cell viral DNA becoming detectable within 6 days of administration. [source, 2016]
A retrospective study was performed using the Original medical records of 1,860 loggerhead turtles admitted to the TWRC, Gran Canaria Island, Spain, from 1998 to 2014. [source, 2016]
Filgrastim, a recombinant G-CSF (rG-CSF) produced in Escherichia coli, was approved by US Food and Drug Administration in 1991. [source, 2016]
Myeloid colonies were also obtained using 30 ng/mL human G-CSF (Amgen), 30 ng/mL murine M-CSF, or 30 ng/mL murine GM-CSF (Peprotech). [source, 2016]
It should be noted that patients who received Docetaxel also received Granulocyte Colony Stimulating Factor (G-CSF) in order to combat neutropenia [7]. [source, 2016]
Briefly, PMBCs that adhered to the tissue culture flask after 2 h were cultured for 7 days in AIM-V media (Invitrogen) containing 100 ng/ml of human Granulocyte Colony Stimulating Factor (GM-CSF) and 20 ng/ml of IL-4 (Miltenyi Biotec, Inc. Auburn, CA). [source, 2016]
The following data of each individual cycle administered were extracted: neutrophils, platelets, and hemoglobin levels at the time of cabazitaxel administration, prophylactic use of G-CSF (granulocyte colony-stimulating factor), total dose of cabazitaxel administered. [source, 2016]
mutation were able to form two- to threefold more colonies than healthy volunteers with wild-type RUNX1 in increasing doses of G-CSF (Figure 6a). [source, 2016]
Granulocyte Colony Stimulating Factor (G-CSF) is given to stimulate peripheral blood stem cells followed by hematopoietic stem cell mobilization four to six days later. [source, 2016]